LaMalfa Supports Coronavirus Emergency Supplemental Package

Mar 5, 2020
Press Release

(Washington, DC) – Congressman Doug LaMalfa (R-Richvale) issued the following statement after voting in support of the House passed $7.8 billion Coronavirus Emergency Supplemental package for the U.S. response to coronavirus.

LaMalfa said: “This package provides the funds necessary for the U.S. to address the virus at home and abroad, including assisting state and local health departments, making diagnostic tests more widely available, investing in the development of a vaccine, and reserving funds to prevent and respond to future diseases. While Americans’ risk of contracting the disease remains low, Congress has taken the right steps to provide for our country’s needs. The Administration has taken the appropriate steps responding to coronavirus so far; I‘m glad that we were able to get this package through.”

The Coronavirus Emergency Supplemental package contains the following appropriations

  • $4 billion to make diagnostic tests more available; to support treatments to ease the symptoms of those infected with the virus; and to invest in vaccine development. Funds are also made available for the FDA to protect the integrity of medical products manufactured overseas and identify and prevent potential shortages.
  • $2.2 billion for the CDC for a strong response including:
    • $950 million exclusively for state and local response efforts; and
    • $300 million for CDC’s Infections Disease Rapid Response Reserve Fund to prevent, prepare for, and respond to diseases
  • $20 million to administer disaster assistance loans for small businesses impacted by the virus
  • $1.25 billion for the State Department and USAID to protect Americans abroad and prevent the spread of the virus worldwide, including
    • $264 million to evacuate Americans and maintain consular operation overseas; and
    • $200 million for USAID’s Emergency Response Fund to prepare for and respond to emerging health threats – working to prevent the spread of illness and infection before it reaches U.S. soil.